



Interrad Medical Receives FDA Clearance of World's First Catheter with Subcutaneous Securement System

Minneapolis, MN (October 2, 2008) - Interrad Medical, Inc. a privately held medical device company, announced today that it has received FDA 510(k) clearance of its SecurAcath(TM) PICC with Subcutaneous Securement System.

Interrad Medical has developed an innovative method for catheter securement called SecurAcath. The SecurAcath System utilizes a small anchor that deploys in the subcutaneous tissue just beneath the skin to hold an indwelling catheter securely in place. There are over 12 million venous access catheters placed each year worldwide. Currently, catheters are secured on the surface of a patient's skin using sutures or adhesive devices.

The SecurAcath System offers potential advantages over current securement methods including; decreasing catheter maintenance time and related costs, decreasing skin surface issues, and eliminating needle stick injuries that can occur when suturing catheters. The SecurAcath system is designed to improve catheter securement and may reduce catheter-related infections by improving cleaning of the catheter exit site and minimizing catheter motion.

Joe Goldberger, Interrad's President and CEO commented, "The first placements of the SecurAcath PICC will begin shortly followed by worldwide commercialization. We believe the SecurAcath System has the potential to become the next standard of care for catheter securement. "

The Company is currently developing a stand-alone SecurAcath device that can be used with virtually any indwelling catheter. The stand-alone SecurAcath is being designed to work with all PICC, CVC, dialysis and drainage catheters.

About Interrad Medical, Inc.

Plymouth, MN based Interrad Medical, Inc. is a developer, manufacturer and marketer of medical devices, designed for minimally-invasive interventional and surgical procedures. The Company was founded by a group of physicians lead by practicing Interventional Radiologist and Interrad Medical Chairman, Michael Rosenberg, M.D. For more information, visit www.interradmedical.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation, clinical trials, the regulatory approval process, reimbursement policies and commercialization of new technologies.

Media Contact:

Jeff Killion
Chief Marketing Officer
Interrad Medical, Inc.
jeff@interradmedical.com

100608